Wegovy Tablets vs Foundayo: What the Studies Can Tell You

Our view

We would not choose between Wegovy tablets and Foundayo by taking the largest weight-loss percentage from each trial. The studies enrolled different groups, measured results at different times and reported more than one kind of analysis. Both medicines deserve a product-specific discussion with the prescriber; the published averages cannot pick a winner for an individual.

Put the study beside the result

OASIS 4 randomized 307 adults without diabetes to daily oral semaglutide 25 mg or placebo, with lifestyle intervention. At week 64, the published estimated mean weight changes were −13.6% and −2.2%, respectively. That was a comparison with placebo, not Foundayo.³

ATTAIN-1 randomized 3,127 adults without diabetes to one of three investigational orforglipron doses or placebo, alongside diet and activity changes. At week 72, the publication reported −11.2% for its highest-dose group and −2.1% for placebo using the treatment-regimen analysis.⁴

The numbers describe results within each study. Subtracting one medicine's percentage from the other's does not create a head-to-head trial. The different follow-up, participants and analytical choices remain. Our injectable semaglutide-versus-tirzepatide comparison concerns another pair of treatments; it cannot fill that gap for these tablets.

Why one trial can have more than one headline

An analysis may ask what happens after assignment to treatment, including interruptions, or estimate what would happen if everyone continued the intended treatment. OASIS 4 called these its treatment-policy and trial-product approaches. ATTAIN-1 likewise distinguished a treatment-regimen analysis from a hypothetical continued-treatment efficacy analysis.^{4, 5}

An estimate that assumes continued treatment is not a promise for everyone who starts a prescription. Ask which analysis a quoted figure uses, whether people who stopped treatment remain represented and how missing measurements were handled. Do not compare one trial's continued-treatment estimate with another's broader treatment-assignment result as though they answered the same question.

The trial dose is not a substitution instruction

ATTAIN-1's publication describes investigational doses of 6, 12 and 36 mg.⁴ The current Foundayo label explains that its clinical-study results came from an investigational formulation and presents them using equivalent marketed dosages.² Those differing milligram numbers are a reason to check the exact formulation, not to work out your own conversion or change tablets.

Wegovy tablets contain semaglutide; Foundayo contains orforglipron.^{1, 2} A matching daily routine or a smaller milligram number does not establish interchangeability. Bring the complete product name and prescription to the pharmacist. Our oral-versus-injectable guide explains the separate distinction between approved tablets and compounded oral preparations.

Count symptoms and stopping treatment separately

OASIS 4's publication reported gastrointestinal adverse events in 74.0% of oral-semaglutide participants and 42.2% of placebo participants.³ ATTAIN-1 reported that gastrointestinal events led to treatment discontinuation in 3.5%–7.0% across its orforglipron groups, versus 0.4% with placebo.⁴

Those are different measures: experiencing an event and stopping because of one. They should not become a two-column “which pill has fewer side effects?” score. Check the event definition, study population and observation period before comparing a percentage. Our side-effects evidence guide gives broader context for trial events and label warnings.

Decide whether the daily routine fits

Wegovy tablets have morning empty-stomach instructions, a water limit and a wait of at least thirty minutes before food, drinks or other oral medicines. Foundayo's label permits once-daily use with or without food.^{1, 2} Ask a pharmacist how the proposed medicine fits your existing prescriptions and routine.

Administration is one part of the choice. Review the exact product's precautions and your medical history with the treating team. Our birth-control guide explains one interaction question that depends on the medicine, rather than simply whether it is swallowed.